#United States #New York #Rosen Law Firm #Securities Class Action #Immutep Ltd.

Rosen Law Firm Presses Immutep Ltd. Investors to Act Now

The legal landscape for investors can be exceptionally challenging, especially when firms find themselves embroiled in allegations of misleading information. This is the current scenario surrounding Immutep Ltd. (NASDAQ: IMMP), as Rosen Law Firm, a globally recognized investor rights law firm, has commenced investigations into potential securities claims on behalf of shareholders. This inquiry arises after serious allegations that the company may have disseminated materially misleading business information to the public.

On March 13, 2026, Immutep released a press statement that indicated the Independent Data Monitoring Committee (IDMC) had recommended the discontinuation of their TACTI-004 Phase III study examining the efficacy of eftilagimod alfa (‘efti’) in patients diagnosed with non-small cell lung cancer. The committee suggested halting the study based on a planned interim futile analysis, a recommendation that led to a drastic decline in Immutep's American Depositary Receipt (ADR) price, which plummeted by approximately 82.6%, closing at $0.48 per ADR.

Given these developments, investors who acquired Immutep’s securities might be entitled to compensation without upfront costs, courtesy of a contingency fee system being organized by the Rosen Law Firm. The firm seeks to recover losses suffered by investors and encourages affected shareholders to take action promptly.

Understanding the Role of Rosen Law Firm

Rosen Law Firm brings significant experience and expertise to the table, particularly in the realm of securities class actions and shareholder derivative litigation. With a robust track record, including being historically recognized for achieving one of the largest securities class action settlements against a Chinese company, the firm has consistently ranked among the top firms in terms of securities class action settlements. Notably, they secured over $438 million for investors in 2019 alone and have been highly commended for their work in the investor rights landscape.

In addition to their impressive settlement record, the firm is led by seasoned attorneys, including founding partner Laurence Rosen, who has garnered accolades such as being named one of the ‘Titans of the Plaintiffs’ Bar’ in 2020 by Law360. Their lawyers have consistently received recognition from top legal authorities, reflecting their commitment to helping investors seek justice.

Taking Action

Investors who feel they may have been misled should consider joining the prospective class action against Immutep Ltd. They can easily initiate the process by visiting the official Rosen Law Firm website at https://rosenlegal.com/submit-form/?case_id=56430. Alternatively, inquiries can be directed to Phillip Kim, Esq., who may be reached toll-free at 866-767-3653 or via email at [email protected].

As the investigation unfolds, the Rosen Law Firm will provide continual updates on their findings and the progression of the class action, available through their social media channels, including LinkedIn, Twitter, and Facebook. They emphasize the importance of selecting reputable legal counsel in such matters to navigate the complexities of securities litigation.

In summary, the situation surrounding Immutep Ltd. serves as a poignant reminder of the risks involved in investing. However, with legal avenues like those being pursued by the Rosen Law Firm, affected investors may find paths toward recovery for their losses. It is critical for investors to stay informed, act decisively, and secure competent legal representation as this case develops.